AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
tranexamic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2713 | 1197-18-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Antifibrinolytic hemostatic used in severe hemorrhage.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | g | O |
| 2 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 34 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.38 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.97 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.30 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 31 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -2.788 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.694 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.964 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 2.692 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 81.850 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 75.380 | % | High | 1 |
| herg | hERG pIC50 | 5.143 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.472 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.614 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 81.430 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK2,PDK4,PRKDC,SYK,TEK,TGFBR1 | 25 | |||
| kinase-selectivity-class | EIF2AK3,MAP2K6 | 2 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.262 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 1.563 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 87.570 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.279 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 83.560 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 2.972 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 81.710 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 94.320 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 843.335 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 30, 1986 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myoclonus | 134.99 | 14.98 | 65 | 14840 | 19103 | 90594439 |
| Aplastic anaemia | 131.26 | 14.98 | 57 | 14848 | 13212 | 90600330 |
| Renal cortical necrosis | 130.52 | 14.98 | 25 | 14880 | 278 | 90613264 |
| Wrong product administered | 124.40 | 14.98 | 47 | 14858 | 7618 | 90605924 |
| Pulmonary embolism | 106.37 | 14.98 | 119 | 14786 | 130701 | 90482841 |
| Generalised tonic-clonic seizure | 98.61 | 14.98 | 65 | 14840 | 34838 | 90578704 |
| Anaphylactic reaction | 96.99 | 14.98 | 94 | 14811 | 87430 | 90526112 |
| Vaginal haemorrhage | 95.12 | 14.98 | 61 | 14844 | 31210 | 90582332 |
| Melaena | 91.56 | 14.98 | 62 | 14843 | 34735 | 90578807 |
| Hereditary angioedema | 88.62 | 14.98 | 39 | 14866 | 9326 | 90604216 |
| Haemorrhage | 83.50 | 14.98 | 78 | 14827 | 69291 | 90544251 |
| Purpura | 80.17 | 14.98 | 42 | 14863 | 14736 | 90598806 |
| Heavy menstrual bleeding | 74.98 | 14.98 | 45 | 14860 | 20485 | 90593057 |
| Platelet count decreased | 73.28 | 14.98 | 101 | 14804 | 136868 | 90476674 |
| Seizure | 72.02 | 14.98 | 106 | 14799 | 152523 | 90461019 |
| Maternal exposure during delivery | 71.27 | 14.98 | 26 | 14879 | 3820 | 90609722 |
| Status epilepticus | 67.97 | 14.98 | 41 | 14864 | 18833 | 90594709 |
| Deep vein thrombosis | 55.79 | 14.98 | 72 | 14833 | 91548 | 90521994 |
| Hypotension | 55.35 | 14.98 | 147 | 14758 | 325250 | 90288292 |
| Cerebral venous sinus thrombosis | 55.20 | 14.98 | 19 | 14886 | 2357 | 90611185 |
| Rash maculo-papular | 53.08 | 14.98 | 48 | 14857 | 40885 | 90572657 |
| Cerebral infarction | 52.94 | 14.98 | 40 | 14865 | 26556 | 90586986 |
| Vasodilatation | 51.60 | 14.98 | 19 | 14886 | 2865 | 90610677 |
| Cardiac arrest | 51.10 | 14.98 | 74 | 14831 | 104861 | 90508681 |
| Tachycardia | 50.58 | 14.98 | 92 | 14813 | 157581 | 90455961 |
| Joint swelling | 49.75 | 14.98 | 11 | 14894 | 503289 | 90110253 |
| Thrombocytopenia | 49.15 | 14.98 | 107 | 14798 | 208618 | 90404924 |
| Febrile neutropenia | 47.79 | 14.98 | 90 | 14815 | 158259 | 90455283 |
| Anaphylactic shock | 44.82 | 14.98 | 39 | 14866 | 31578 | 90581964 |
| Alopecia | 44.73 | 14.98 | 13 | 14892 | 495058 | 90118484 |
| Fatigue | 44.68 | 14.98 | 76 | 14829 | 1153947 | 89459595 |
| Angioedema | 44.30 | 14.98 | 54 | 14851 | 64822 | 90548720 |
| Drug hypersensitivity | 44.09 | 14.98 | 11 | 14894 | 463598 | 90149944 |
| Acute myocardial infarction | 43.45 | 14.98 | 40 | 14865 | 34850 | 90578692 |
| Transfusion | 43.24 | 14.98 | 30 | 14875 | 17458 | 90596084 |
| Off label use | 43.21 | 14.98 | 319 | 14586 | 1101933 | 89511609 |
| Uterine haemorrhage | 42.42 | 14.98 | 19 | 14886 | 4733 | 90608809 |
| Systemic lupus erythematosus | 42.23 | 14.98 | 5 | 14900 | 361891 | 90251651 |
| Ovarian vein thrombosis | 41.93 | 14.98 | 8 | 14897 | 87 | 90613455 |
| Drug intolerance | 41.83 | 14.98 | 11 | 14894 | 447580 | 90165962 |
| Myoclonic epilepsy | 41.68 | 14.98 | 14 | 14891 | 1613 | 90611929 |
| Incorrect route of product administration | 41.00 | 14.98 | 46 | 14859 | 50580 | 90562962 |
| Biliary sepsis | 39.82 | 14.98 | 12 | 14893 | 974 | 90612568 |
| Hepatic function abnormal | 39.10 | 14.98 | 43 | 14862 | 46245 | 90567297 |
| Epistaxis | 38.51 | 14.98 | 58 | 14847 | 85067 | 90528475 |
| Enterococcal sepsis | 37.84 | 14.98 | 13 | 14892 | 1603 | 90611939 |
| Shock haemorrhagic | 37.50 | 14.98 | 24 | 14881 | 12221 | 90601321 |
| Brain oedema | 36.50 | 14.98 | 27 | 14878 | 17358 | 90596184 |
| Contraindicated product administered | 35.96 | 14.98 | 5 | 14900 | 320134 | 90293408 |
| Rheumatoid arthritis | 35.66 | 14.98 | 8 | 14897 | 362606 | 90250936 |
| Neutropenic sepsis | 35.49 | 14.98 | 27 | 14878 | 18103 | 90595439 |
| Haemoptysis | 35.41 | 14.98 | 35 | 14870 | 33285 | 90580257 |
| Product packaging confusion | 34.77 | 14.98 | 8 | 14897 | 225 | 90613317 |
| Rash erythematous | 34.77 | 14.98 | 48 | 14857 | 65056 | 90548486 |
| Mucosal inflammation | 34.62 | 14.98 | 45 | 14860 | 57580 | 90555962 |
| Abdominal discomfort | 34.12 | 14.98 | 18 | 14887 | 477310 | 90136232 |
| Retinal artery occlusion | 33.53 | 14.98 | 13 | 14892 | 2258 | 90611284 |
| Pericarditis | 33.40 | 14.98 | 3 | 14902 | 270148 | 90343394 |
| Sepsis | 33.37 | 14.98 | 84 | 14821 | 179730 | 90433812 |
| Haemoglobin decreased | 32.53 | 14.98 | 78 | 14827 | 161878 | 90451664 |
| Infusion related reaction | 32.41 | 14.98 | 14 | 14891 | 416766 | 90196776 |
| Ureteric perforation | 31.89 | 14.98 | 5 | 14900 | 14 | 90613528 |
| Puncture site haematoma | 31.46 | 14.98 | 6 | 14899 | 65 | 90613477 |
| Blood pressure decreased | 31.02 | 14.98 | 49 | 14856 | 74846 | 90538696 |
| Drug ineffective for unapproved indication | 30.98 | 14.98 | 46 | 14859 | 66598 | 90546944 |
| Haemorrhage intracranial | 30.61 | 14.98 | 23 | 14882 | 15139 | 90598403 |
| Tri-iodothyronine free decreased | 30.42 | 14.98 | 8 | 14897 | 395 | 90613147 |
| Tonic clonic movements | 29.54 | 14.98 | 11 | 14894 | 1711 | 90611831 |
| Pain | 28.97 | 14.98 | 77 | 14828 | 996264 | 89617278 |
| Toxic epidermal necrolysis | 28.84 | 14.98 | 31 | 14874 | 32497 | 90581045 |
| Ischaemic stroke | 28.74 | 14.98 | 26 | 14879 | 22140 | 90591402 |
| Acute left ventricular failure | 28.70 | 14.98 | 10 | 14895 | 1286 | 90612256 |
| Nosocomial infection | 28.42 | 14.98 | 11 | 14894 | 1902 | 90611640 |
| Alanine aminotransferase increased | 28.21 | 14.98 | 61 | 14844 | 118277 | 90495265 |
| Acute generalised exanthematous pustulosis | 28.14 | 14.98 | 21 | 14884 | 13682 | 90599860 |
| Infusion site scar | 27.19 | 14.98 | 8 | 14897 | 598 | 90612944 |
| Haemorrhagic disorder | 27.08 | 14.98 | 9 | 14896 | 1003 | 90612539 |
| Stridor | 27.07 | 14.98 | 14 | 14891 | 4779 | 90608763 |
| Psoriatic arthropathy | 27.01 | 14.98 | 3 | 14902 | 228332 | 90385210 |
| Pulmonary alveolar haemorrhage | 26.82 | 14.98 | 15 | 14890 | 5983 | 90607559 |
| Anaemia | 26.09 | 14.98 | 121 | 14784 | 352681 | 90260861 |
| Coronary artery thrombosis | 26.02 | 14.98 | 9 | 14896 | 1133 | 90612409 |
| Basophil count increased | 25.95 | 14.98 | 9 | 14896 | 1142 | 90612400 |
| Puncture site haemorrhage | 25.77 | 14.98 | 7 | 14898 | 391 | 90613151 |
| Mobility decreased | 25.73 | 14.98 | 5 | 14900 | 250729 | 90362813 |
| Uterine disorder | 25.70 | 14.98 | 12 | 14893 | 3289 | 90610253 |
| Factor VII deficiency | 25.45 | 14.98 | 5 | 14900 | 64 | 90613478 |
| Urine ketone body present | 25.35 | 14.98 | 11 | 14894 | 2541 | 90611001 |
| Multiple organ dysfunction syndrome | 24.64 | 14.98 | 42 | 14863 | 68294 | 90545248 |
| Perforation | 24.51 | 14.98 | 10 | 14895 | 1984 | 90611558 |
| Asthma | 24.49 | 14.98 | 5 | 14900 | 242155 | 90371387 |
| Platelet count increased | 24.21 | 14.98 | 23 | 14882 | 20836 | 90592706 |
| Haemodynamic instability | 24.13 | 14.98 | 18 | 14887 | 11721 | 90601821 |
| Weight increased | 24.12 | 14.98 | 20 | 14885 | 417907 | 90195635 |
| Electrocardiogram PR shortened | 23.65 | 14.98 | 7 | 14898 | 534 | 90613008 |
| Poor venous access | 23.56 | 14.98 | 22 | 14883 | 19505 | 90594037 |
| Cancer pain | 23.44 | 14.98 | 12 | 14893 | 4013 | 90609529 |
| Atrial thrombosis | 23.36 | 14.98 | 10 | 14895 | 2235 | 90611307 |
| Embolic stroke | 23.30 | 14.98 | 12 | 14893 | 4060 | 90609482 |
| Uterine leiomyoma | 23.09 | 14.98 | 17 | 14888 | 10847 | 90602695 |
| Premature delivery | 22.86 | 14.98 | 30 | 14875 | 38732 | 90574810 |
| Postpartum haemorrhage | 22.72 | 14.98 | 10 | 14895 | 2391 | 90611151 |
| Circulatory collapse | 22.54 | 14.98 | 24 | 14881 | 24880 | 90588662 |
| Thrombosis | 22.53 | 14.98 | 42 | 14863 | 73209 | 90540333 |
| Platelet transfusion | 22.36 | 14.98 | 8 | 14897 | 1112 | 90612430 |
| Product dose omission issue | 22.34 | 14.98 | 10 | 14895 | 291677 | 90321865 |
| Wound | 22.26 | 14.98 | 11 | 14894 | 302969 | 90310573 |
| Urinary tract disorder | 21.42 | 14.98 | 11 | 14894 | 3700 | 90609842 |
| Rectal haemorrhage | 21.27 | 14.98 | 44 | 14861 | 82700 | 90530842 |
| Type 2 diabetes mellitus | 20.96 | 14.98 | 4 | 14901 | 203240 | 90410302 |
| Extravasation | 20.70 | 14.98 | 10 | 14895 | 2954 | 90610588 |
| Pulmonary haemorrhage | 20.41 | 14.98 | 14 | 14891 | 7999 | 90605543 |
| Infusion site warmth | 20.38 | 14.98 | 9 | 14896 | 2169 | 90611373 |
| Hypoventilation | 20.35 | 14.98 | 12 | 14893 | 5284 | 90608258 |
| Coagulopathy | 20.30 | 14.98 | 22 | 14883 | 23267 | 90590275 |
| Memory impairment | 20.09 | 14.98 | 4 | 14901 | 197240 | 90416302 |
| Meningitis aseptic | 20.06 | 14.98 | 13 | 14892 | 6760 | 90606782 |
| Stress cardiomyopathy | 19.99 | 14.98 | 17 | 14888 | 13338 | 90600204 |
| Hepatic enzyme increased | 19.92 | 14.98 | 18 | 14887 | 360718 | 90252824 |
| Gastrointestinal haemorrhage | 19.79 | 14.98 | 45 | 14860 | 90203 | 90523339 |
| Blood cholesterol increased | 19.62 | 14.98 | 5 | 14900 | 208007 | 90405535 |
| Impaired healing | 19.61 | 14.98 | 7 | 14898 | 234192 | 90379350 |
| Fibroma | 19.59 | 14.98 | 7 | 14898 | 969 | 90612573 |
| Arterial thrombosis | 19.58 | 14.98 | 8 | 14897 | 1592 | 90611950 |
| Stevens-Johnson syndrome | 19.31 | 14.98 | 24 | 14881 | 29352 | 90584190 |
| Disinhibition | 18.97 | 14.98 | 7 | 14898 | 1061 | 90612481 |
| Infusion site discomfort | 18.60 | 14.98 | 8 | 14897 | 1808 | 90611734 |
| Lower respiratory tract infection | 18.56 | 14.98 | 9 | 14896 | 250650 | 90362892 |
| Drug interaction | 18.38 | 14.98 | 92 | 14813 | 276361 | 90337181 |
| Injury | 18.13 | 14.98 | 5 | 14900 | 197344 | 90416198 |
| Sinusitis | 17.91 | 14.98 | 18 | 14887 | 343070 | 90270472 |
| Ischaemia | 17.77 | 14.98 | 11 | 14894 | 5284 | 90608258 |
| Cerebral haemorrhage | 17.75 | 14.98 | 25 | 14880 | 34497 | 90579045 |
| Toxic skin eruption | 17.56 | 14.98 | 17 | 14888 | 15757 | 90597785 |
| Fibromyalgia | 17.56 | 14.98 | 6 | 14899 | 206263 | 90407279 |
| Uterine atony | 17.41 | 14.98 | 5 | 14900 | 343 | 90613199 |
| Venous thrombosis | 17.32 | 14.98 | 11 | 14894 | 5526 | 90608016 |
| Ventricular fibrillation | 17.28 | 14.98 | 16 | 14889 | 14028 | 90599514 |
| Asthenia | 17.22 | 14.98 | 39 | 14866 | 533712 | 90079830 |
| Allergic reaction to excipient | 17.14 | 14.98 | 6 | 14899 | 782 | 90612760 |
| Enterocolitis | 17.04 | 14.98 | 14 | 14891 | 10476 | 90603066 |
| Caesarean section | 16.99 | 14.98 | 18 | 14887 | 18559 | 90594983 |
| PCO2 abnormal | 16.98 | 14.98 | 4 | 14901 | 125 | 90613417 |
| Drug ineffective | 16.90 | 14.98 | 320 | 14585 | 1383978 | 89229564 |
| Hyperaesthesia | 16.80 | 14.98 | 14 | 14891 | 10688 | 90602854 |
| Acute respiratory distress syndrome | 16.60 | 14.98 | 22 | 14883 | 28664 | 90584878 |
| Nasopharyngitis | 16.42 | 14.98 | 26 | 14879 | 407078 | 90206464 |
| Ill-defined disorder | 16.40 | 14.98 | 5 | 14900 | 184886 | 90428656 |
| Dry mouth | 16.29 | 14.98 | 5 | 14900 | 184054 | 90429488 |
| Infusion site rash | 16.21 | 14.98 | 8 | 14897 | 2475 | 90611067 |
| Pancytopenia | 16.18 | 14.98 | 50 | 14855 | 120213 | 90493329 |
| Arterial haemorrhage | 16.09 | 14.98 | 8 | 14897 | 2515 | 90611027 |
| Discomfort | 15.98 | 14.98 | 13 | 14892 | 274322 | 90339220 |
| HER2 positive breast cancer | 15.93 | 14.98 | 5 | 14900 | 465 | 90613077 |
| Thoracotomy | 15.69 | 14.98 | 3 | 14902 | 33 | 90613509 |
| Upper respiratory tract inflammation | 15.66 | 14.98 | 8 | 14897 | 2664 | 90610878 |
| False negative investigation result | 15.50 | 14.98 | 4 | 14901 | 183 | 90613359 |
| Upper gastrointestinal haemorrhage | 15.47 | 14.98 | 19 | 14886 | 22957 | 90590585 |
| Acute myeloid leukaemia | 15.43 | 14.98 | 18 | 14887 | 20622 | 90592920 |
| Adnexal torsion | 15.30 | 14.98 | 5 | 14900 | 529 | 90613013 |
| Blood lactate dehydrogenase increased | 15.18 | 14.98 | 20 | 14885 | 25912 | 90587630 |
| Colitis ischaemic | 15.07 | 14.98 | 14 | 14891 | 12332 | 90601210 |
| Psoriasis | 15.04 | 14.98 | 3 | 14902 | 147751 | 90465791 |
| Shock | 15.03 | 14.98 | 21 | 14884 | 28757 | 90584785 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic reaction | 147.92 | 16.84 | 109 | 11374 | 42634 | 42567218 |
| Haemorrhage | 142.27 | 16.84 | 123 | 11360 | 60440 | 42549412 |
| Myoclonus | 111.93 | 16.84 | 65 | 11418 | 17000 | 42592852 |
| Factor VIII inhibition | 88.91 | 16.84 | 20 | 11463 | 302 | 42609550 |
| Mechanical ventilation complication | 87.57 | 16.84 | 23 | 11460 | 681 | 42609171 |
| Febrile neutropenia | 86.14 | 16.84 | 168 | 11315 | 185535 | 42424317 |
| Haemothorax | 75.66 | 16.84 | 34 | 11449 | 5202 | 42604650 |
| Wrong product administered | 73.06 | 16.84 | 35 | 11448 | 6191 | 42603661 |
| Haemarthrosis | 67.61 | 16.84 | 29 | 11454 | 3969 | 42605883 |
| Generalised tonic-clonic seizure | 66.81 | 16.84 | 56 | 11427 | 26323 | 42583529 |
| Anaphylactic shock | 66.01 | 16.84 | 53 | 11430 | 23464 | 42586388 |
| Aplastic anaemia | 62.75 | 16.84 | 40 | 11443 | 12344 | 42597508 |
| Inspiratory capacity decreased | 58.47 | 16.84 | 24 | 11459 | 2943 | 42606909 |
| Shock haemorrhagic | 52.94 | 16.84 | 40 | 11443 | 16202 | 42593650 |
| Vasodilatation | 49.66 | 16.84 | 17 | 11466 | 1260 | 42608592 |
| Adverse reaction | 48.53 | 16.84 | 23 | 11460 | 3970 | 42605882 |
| Status epilepticus | 47.78 | 16.84 | 37 | 11446 | 15541 | 42594311 |
| Post procedural haemorrhage | 46.98 | 16.84 | 30 | 11453 | 9282 | 42600570 |
| Post procedural hypotension | 45.45 | 16.84 | 9 | 11474 | 70 | 42609782 |
| Muscle haemorrhage | 44.81 | 16.84 | 22 | 11461 | 4103 | 42605749 |
| Vascular stent thrombosis | 43.51 | 16.84 | 20 | 11463 | 3222 | 42606630 |
| Cerebral infarction | 42.41 | 16.84 | 47 | 11436 | 31122 | 42578730 |
| Angiopathy | 42.06 | 16.84 | 23 | 11460 | 5354 | 42604498 |
| Epistaxis | 41.82 | 16.84 | 69 | 11414 | 66757 | 42543095 |
| Mucosal inflammation | 39.33 | 16.84 | 57 | 11426 | 49317 | 42560535 |
| Tachycardia | 39.12 | 16.84 | 85 | 11398 | 101002 | 42508850 |
| Platelet count decreased | 39.05 | 16.84 | 103 | 11380 | 138478 | 42471374 |
| Urticaria | 35.45 | 16.84 | 68 | 11415 | 73968 | 42535884 |
| Face oedema | 34.56 | 16.84 | 29 | 11454 | 13637 | 42596215 |
| Myoclonic epilepsy | 34.55 | 16.84 | 14 | 11469 | 1660 | 42608192 |
| Emphysema | 33.89 | 16.84 | 27 | 11456 | 11808 | 42598044 |
| Hypovolaemia | 32.46 | 16.84 | 26 | 11457 | 11459 | 42598393 |
| Haemophilia | 32.16 | 16.84 | 5 | 11478 | 6 | 42609846 |
| Fatigue | 31.44 | 16.84 | 43 | 11440 | 435598 | 42174254 |
| Pneumothorax | 31.16 | 16.84 | 35 | 11448 | 23508 | 42586344 |
| Mesenteric vascular insufficiency | 31.10 | 16.84 | 7 | 11476 | 106 | 42609746 |
| Coronary artery thrombosis | 30.36 | 16.84 | 14 | 11469 | 2272 | 42607580 |
| Incorrect route of product administration | 30.25 | 16.84 | 35 | 11448 | 24270 | 42585582 |
| Upper respiratory tract inflammation | 29.60 | 16.84 | 13 | 11470 | 1883 | 42607969 |
| Interstitial lung disease | 29.24 | 16.84 | 65 | 11418 | 78397 | 42531455 |
| Product dose omission issue | 28.28 | 16.84 | 4 | 11479 | 154361 | 42455491 |
| Haemoptysis | 25.35 | 16.84 | 45 | 11438 | 46122 | 42563730 |
| Platelet transfusion | 24.47 | 16.84 | 11 | 11472 | 1683 | 42608169 |
| Gingival bleeding | 23.53 | 16.84 | 19 | 11464 | 8466 | 42601386 |
| Hypotension | 23.08 | 16.84 | 133 | 11350 | 257498 | 42352354 |
| Hepatic function abnormal | 23.01 | 16.84 | 46 | 11437 | 51521 | 42558331 |
| Pulmonary haemorrhage | 22.46 | 16.84 | 21 | 11462 | 11376 | 42598476 |
| Inhibiting antibodies positive | 21.66 | 16.84 | 3 | 11480 | 0 | 42609852 |
| Tryptase decreased | 21.10 | 16.84 | 4 | 11479 | 24 | 42609828 |
| Immune thrombocytopenia | 20.83 | 16.84 | 20 | 11463 | 11196 | 42598656 |
| Gastrointestinal haemorrhage | 20.14 | 16.84 | 65 | 11418 | 97661 | 42512191 |
| Haemoglobin increased | 19.62 | 16.84 | 14 | 11469 | 5192 | 42604660 |
| Chronic pulmonary histoplasmosis | 19.58 | 16.84 | 3 | 11480 | 3 | 42609849 |
| Clonus | 19.41 | 16.84 | 12 | 11471 | 3508 | 42606344 |
| Toxicity to various agents | 19.27 | 16.84 | 20 | 11463 | 229116 | 42380736 |
| Bronchospasm | 18.51 | 16.84 | 20 | 11463 | 12865 | 42596987 |
| Acute myocardial infarction | 18.18 | 16.84 | 45 | 11438 | 58120 | 42551732 |
| Labile blood pressure | 18.08 | 16.84 | 7 | 11476 | 736 | 42609116 |
| Pneumonia | 17.98 | 16.84 | 183 | 11300 | 421966 | 42187886 |
| Haemorrhagic diathesis | 17.91 | 16.84 | 11 | 11472 | 3178 | 42606674 |
| Pleural effusion | 17.69 | 16.84 | 62 | 11421 | 97104 | 42512748 |
| Hepatic cyst ruptured | 17.50 | 16.84 | 3 | 11480 | 9 | 42609843 |
| Death | 17.29 | 16.84 | 67 | 11416 | 471118 | 42138734 |
| Fibrin degradation products increased | 16.95 | 16.84 | 5 | 11478 | 228 | 42609624 |
| Nystagmus | 16.94 | 16.84 | 13 | 11470 | 5383 | 42604469 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic reaction | 233.37 | 13.62 | 199 | 24846 | 114101 | 110450153 |
| Myoclonus | 212.57 | 13.62 | 117 | 24928 | 32881 | 110531373 |
| Haemorrhage | 208.14 | 13.62 | 181 | 24864 | 106511 | 110457743 |
| Wrong product administered | 196.97 | 13.62 | 79 | 24966 | 10881 | 110553373 |
| Aplastic anaemia | 184.10 | 13.62 | 96 | 24949 | 24212 | 110540042 |
| Generalised tonic-clonic seizure | 167.43 | 13.62 | 121 | 24924 | 54559 | 110509695 |
| Renal cortical necrosis | 108.89 | 13.62 | 25 | 25020 | 499 | 110563755 |
| Status epilepticus | 108.52 | 13.62 | 75 | 24970 | 31496 | 110532758 |
| Febrile neutropenia | 107.87 | 13.62 | 228 | 24817 | 316539 | 110247715 |
| Anaphylactic shock | 107.67 | 13.62 | 91 | 24954 | 51455 | 110512799 |
| Platelet count decreased | 104.21 | 13.62 | 187 | 24858 | 230256 | 110333998 |
| Vasodilatation | 99.82 | 13.62 | 36 | 25009 | 3708 | 110560546 |
| Mechanical ventilation complication | 89.44 | 13.62 | 23 | 25022 | 748 | 110563506 |
| Shock haemorrhagic | 87.29 | 13.62 | 62 | 24983 | 27185 | 110537069 |
| Cerebral infarction | 87.29 | 13.62 | 81 | 24964 | 51757 | 110512497 |
| Haemothorax | 84.17 | 13.62 | 38 | 25007 | 6993 | 110557261 |
| Hereditary angioedema | 83.74 | 13.62 | 38 | 25007 | 7076 | 110557178 |
| Myoclonic epilepsy | 79.79 | 13.62 | 28 | 25017 | 2663 | 110561591 |
| Factor VIII inhibition | 79.74 | 13.62 | 18 | 25027 | 332 | 110563922 |
| Tachycardia | 76.93 | 13.62 | 163 | 24882 | 226482 | 110337772 |
| Vaginal haemorrhage | 73.35 | 13.62 | 54 | 24991 | 25020 | 110539234 |
| Melaena | 71.56 | 13.62 | 83 | 24962 | 68674 | 110495580 |
| Epistaxis | 71.04 | 13.62 | 115 | 24930 | 130257 | 110433997 |
| Fatigue | 69.72 | 13.62 | 105 | 24940 | 1215853 | 109348401 |
| Pulmonary embolism | 69.05 | 13.62 | 151 | 24894 | 214323 | 110349931 |
| Inspiratory capacity decreased | 65.63 | 13.62 | 24 | 25021 | 2571 | 110561683 |
| Mucosal inflammation | 65.36 | 13.62 | 94 | 24951 | 96047 | 110468207 |
| Maternal exposure during delivery | 61.64 | 13.62 | 25 | 25020 | 3540 | 110560714 |
| Haemarthrosis | 61.42 | 13.62 | 31 | 25014 | 7298 | 110556956 |
| Incorrect route of product administration | 61.15 | 13.62 | 74 | 24971 | 63987 | 110500267 |
| Seizure | 60.46 | 13.62 | 146 | 24899 | 221039 | 110343215 |
| Heavy menstrual bleeding | 58.89 | 13.62 | 40 | 25005 | 16325 | 110547929 |
| Hypotension | 57.60 | 13.62 | 253 | 24792 | 523596 | 110040658 |
| Acute myocardial infarction | 57.08 | 13.62 | 82 | 24963 | 83695 | 110480559 |
| Coronary artery thrombosis | 56.95 | 13.62 | 23 | 25022 | 3221 | 110561033 |
| Post procedural hypotension | 56.32 | 13.62 | 11 | 25034 | 96 | 110564158 |
| Hepatic function abnormal | 55.92 | 13.62 | 84 | 24961 | 89211 | 110475043 |
| Drug intolerance | 55.74 | 13.62 | 12 | 25033 | 406500 | 110157754 |
| Haemoptysis | 54.82 | 13.62 | 74 | 24971 | 71280 | 110492974 |
| Purpura | 52.86 | 13.62 | 44 | 25001 | 24344 | 110539910 |
| Joint swelling | 51.51 | 13.62 | 18 | 25027 | 442827 | 110121427 |
| Synovitis | 50.05 | 13.62 | 3 | 25042 | 274089 | 110290165 |
| Arthropathy | 50.03 | 13.62 | 4 | 25041 | 287518 | 110276736 |
| Rash maculo-papular | 49.61 | 13.62 | 72 | 24973 | 74150 | 110490104 |
| Post procedural haemorrhage | 48.99 | 13.62 | 35 | 25010 | 15477 | 110548777 |
| Drug hypersensitivity | 47.04 | 13.62 | 22 | 25023 | 454068 | 110110186 |
| Platelet transfusion | 45.94 | 13.62 | 19 | 25026 | 2827 | 110561427 |
| Deep vein thrombosis | 45.58 | 13.62 | 99 | 24946 | 139788 | 110424466 |
| Cardiac arrest | 44.55 | 13.62 | 121 | 24924 | 196632 | 110367622 |
| Alopecia | 43.85 | 13.62 | 14 | 25031 | 364739 | 110199515 |
| Drug ineffective | 43.59 | 13.62 | 530 | 24515 | 1520010 | 109044244 |
| Muscle haemorrhage | 43.23 | 13.62 | 24 | 25021 | 6845 | 110557409 |
| Cerebral venous sinus thrombosis | 42.29 | 13.62 | 18 | 25027 | 2877 | 110561377 |
| Uterine haemorrhage | 42.19 | 13.62 | 19 | 25026 | 3475 | 110560779 |
| Product packaging confusion | 42.19 | 13.62 | 11 | 25034 | 378 | 110563876 |
| Product dose omission issue | 41.15 | 13.62 | 11 | 25034 | 321771 | 110242483 |
| Rheumatoid arthritis | 40.74 | 13.62 | 9 | 25036 | 299604 | 110264650 |
| Angiopathy | 40.42 | 13.62 | 25 | 25020 | 8705 | 110555549 |
| Blood pressure decreased | 39.27 | 13.62 | 83 | 24962 | 115008 | 110449246 |
| Upper respiratory tract inflammation | 38.13 | 13.62 | 19 | 25026 | 4352 | 110559902 |
| Systemic lupus erythematosus | 38.08 | 13.62 | 6 | 25039 | 254332 | 110309922 |
| Vascular stent thrombosis | 36.04 | 13.62 | 18 | 25027 | 4143 | 110560111 |
| Pericarditis | 35.59 | 13.62 | 4 | 25041 | 219110 | 110345144 |
| Asthma | 35.09 | 13.62 | 7 | 25038 | 250284 | 110313970 |
| Pain | 34.93 | 13.62 | 106 | 24939 | 954849 | 109609405 |
| Infusion related reaction | 34.33 | 13.62 | 22 | 25023 | 381140 | 110183114 |
| Ovarian vein thrombosis | 34.29 | 13.62 | 7 | 25038 | 78 | 110564176 |
| Pulmonary haemorrhage | 34.24 | 13.62 | 29 | 25016 | 16427 | 110547827 |
| Thrombocytopenia | 34.19 | 13.62 | 163 | 24882 | 348722 | 110215532 |
| Transfusion | 33.89 | 13.62 | 35 | 25010 | 25437 | 110538817 |
| Immune thrombocytopenia | 33.77 | 13.62 | 33 | 25012 | 22461 | 110541793 |
| Gastrointestinal haemorrhage | 33.74 | 13.62 | 98 | 24947 | 165420 | 110398834 |
| Drug ineffective for unapproved indication | 33.74 | 13.62 | 73 | 24972 | 102765 | 110461489 |
| Hypovolaemia | 32.92 | 13.62 | 32 | 25013 | 21642 | 110542612 |
| Retinal artery occlusion | 32.79 | 13.62 | 17 | 25028 | 4232 | 110560022 |
| Stridor | 32.57 | 13.62 | 20 | 25025 | 6875 | 110557379 |
| Face oedema | 32.49 | 13.62 | 39 | 25006 | 33430 | 110530824 |
| Pneumothorax | 32.43 | 13.62 | 40 | 25005 | 35245 | 110529009 |
| Tonic clonic movements | 32.33 | 13.62 | 15 | 25030 | 2937 | 110561317 |
| Dry mouth | 31.61 | 13.62 | 4 | 25041 | 199944 | 110364310 |
| Cerebral haemorrhage | 30.96 | 13.62 | 54 | 24991 | 64914 | 110499340 |
| Enterococcal sepsis | 30.69 | 13.62 | 15 | 25030 | 3297 | 110560957 |
| Mesenteric vascular insufficiency | 30.62 | 13.62 | 7 | 25038 | 137 | 110564117 |
| Mobility decreased | 30.57 | 13.62 | 8 | 25037 | 237414 | 110326840 |
| Shock | 30.16 | 13.62 | 48 | 24997 | 53540 | 110510714 |
| Asthenia | 30.07 | 13.62 | 70 | 24975 | 688929 | 109875325 |
| Haemodynamic instability | 29.64 | 13.62 | 31 | 25014 | 22857 | 110541397 |
| Ureteric perforation | 29.56 | 13.62 | 5 | 25040 | 17 | 110564237 |
| Acute generalised exanthematous pustulosis | 29.24 | 13.62 | 30 | 25015 | 21634 | 110542620 |
| Off label use | 28.91 | 13.62 | 488 | 24557 | 1499697 | 109064557 |
| Abdominal discomfort | 28.83 | 13.62 | 28 | 25017 | 393830 | 110170424 |
| Drug eruption | 28.75 | 13.62 | 47 | 24998 | 53612 | 110510642 |
| Biliary sepsis | 28.72 | 13.62 | 12 | 25033 | 1831 | 110562423 |
| Neutropenic sepsis | 28.50 | 13.62 | 35 | 25010 | 30711 | 110533543 |
| Weight increased | 28.28 | 13.62 | 32 | 25013 | 419612 | 110144642 |
| Angioedema | 27.94 | 13.62 | 66 | 24979 | 98434 | 110465820 |
| Interstitial lung disease | 27.92 | 13.62 | 82 | 24963 | 139252 | 110425002 |
| Platelet count increased | 27.74 | 13.62 | 32 | 25013 | 26302 | 110537952 |
| Haemoglobin increased | 27.43 | 13.62 | 20 | 25025 | 9127 | 110555127 |
| Infusion site scar | 27.26 | 13.62 | 8 | 25037 | 428 | 110563826 |
| Factor VII deficiency | 27.04 | 13.62 | 6 | 25039 | 102 | 110564152 |
| Injury | 26.95 | 13.62 | 4 | 25041 | 177261 | 110386993 |
| Tri-iodothyronine free decreased | 26.85 | 13.62 | 8 | 25037 | 451 | 110563803 |
| Brain oedema | 26.59 | 13.62 | 34 | 25011 | 31064 | 110533190 |
| Haemoglobin decreased | 26.41 | 13.62 | 119 | 24926 | 248608 | 110315646 |
| Blood cholesterol increased | 26.25 | 13.62 | 5 | 25040 | 184780 | 110379474 |
| Haemorrhagic diathesis | 26.18 | 13.62 | 18 | 25027 | 7490 | 110556764 |
| Contraindicated product administered | 25.73 | 13.62 | 12 | 25033 | 248255 | 110315999 |
| Rash erythematous | 25.60 | 13.62 | 57 | 24988 | 81775 | 110482479 |
| Thrombotic microangiopathy | 25.13 | 13.62 | 32 | 25013 | 29117 | 110535137 |
| Circulatory collapse | 24.87 | 13.62 | 39 | 25006 | 42954 | 110521300 |
| Anaemia | 24.33 | 13.62 | 209 | 24836 | 546877 | 110017377 |
| Alanine aminotransferase increased | 24.26 | 13.62 | 94 | 24951 | 183679 | 110380575 |
| Emphysema | 24.24 | 13.62 | 26 | 25019 | 19730 | 110544524 |
| Musculoskeletal stiffness | 24.05 | 13.62 | 17 | 25028 | 279805 | 110284449 |
| Haemorrhage intracranial | 23.71 | 13.62 | 31 | 25014 | 28938 | 110535316 |
| Fibromyalgia | 23.50 | 13.62 | 5 | 25040 | 170904 | 110393350 |
| Arterial haemorrhage | 23.10 | 13.62 | 13 | 25032 | 3806 | 110560448 |
| Uterine disorder | 22.96 | 13.62 | 11 | 25034 | 2315 | 110561939 |
| Depression | 22.71 | 13.62 | 23 | 25022 | 317312 | 110246942 |
| Basophil count increased | 22.36 | 13.62 | 10 | 25035 | 1800 | 110562454 |
| Perforation | 22.36 | 13.62 | 10 | 25035 | 1800 | 110562454 |
| Multiple organ dysfunction syndrome | 22.02 | 13.62 | 80 | 24965 | 151630 | 110412624 |
| Lower respiratory tract infection | 21.92 | 13.62 | 14 | 25031 | 243092 | 110321162 |
| Sinusitis | 21.81 | 13.62 | 21 | 25024 | 296667 | 110267587 |
| Helicobacter infection | 21.81 | 13.62 | 7 | 25038 | 181870 | 110382384 |
| Tryptase decreased | 21.65 | 13.62 | 4 | 25041 | 25 | 110564229 |
| Toxicity to various agents | 21.61 | 13.62 | 48 | 24997 | 480507 | 110083747 |
| Embolic stroke | 21.54 | 13.62 | 17 | 25028 | 8726 | 110555528 |
| Puncture site haematoma | 21.49 | 13.62 | 6 | 25039 | 268 | 110563986 |
| Gastrooesophageal reflux disease | 21.45 | 13.62 | 7 | 25038 | 179969 | 110384285 |
| Procedural haemorrhage | 21.29 | 13.62 | 14 | 25031 | 5413 | 110558841 |
| Peripheral swelling | 21.06 | 13.62 | 37 | 25008 | 403997 | 110160257 |
| Ill-defined disorder | 20.74 | 13.62 | 5 | 25040 | 156848 | 110407406 |
| Night sweats | 20.42 | 13.62 | 3 | 25042 | 133980 | 110430274 |
| Chronic pulmonary histoplasmosis | 20.10 | 13.62 | 3 | 25042 | 3 | 110564251 |
| Inhibiting antibodies positive | 20.10 | 13.62 | 3 | 25042 | 3 | 110564251 |
| Acute left ventricular failure | 20.07 | 13.62 | 10 | 25035 | 2291 | 110561963 |
| Neurotoxicity | 20.00 | 13.62 | 35 | 25010 | 42172 | 110522082 |
| Enterocolitis | 19.91 | 13.62 | 23 | 25022 | 18926 | 110545328 |
| Acute myeloid leukaemia | 19.90 | 13.62 | 33 | 25012 | 38077 | 110526177 |
| Pyrexia | 19.77 | 13.62 | 299 | 24746 | 897966 | 109666288 |
| Nosocomial infection | 19.65 | 13.62 | 11 | 25034 | 3188 | 110561066 |
| Impaired healing | 19.63 | 13.62 | 10 | 25035 | 196707 | 110367547 |
| Therapeutic product effect decreased | 19.51 | 13.62 | 16 | 25029 | 244300 | 110319954 |
| Coagulopathy | 19.48 | 13.62 | 34 | 25011 | 40877 | 110523377 |
| Clonus | 19.46 | 13.62 | 16 | 25029 | 8700 | 110555554 |
| Loss of personal independence in daily activities | 19.41 | 13.62 | 5 | 25040 | 150015 | 110414239 |
| Condition aggravated | 19.41 | 13.62 | 93 | 24952 | 734743 | 109829511 |
| Infusion site warmth | 19.39 | 13.62 | 9 | 25036 | 1764 | 110562490 |
| Puncture site haemorrhage | 19.37 | 13.62 | 7 | 25038 | 725 | 110563529 |
| Type 2 diabetes mellitus | 19.26 | 13.62 | 8 | 25037 | 177224 | 110387030 |
| Gingival bleeding | 19.06 | 13.62 | 23 | 25022 | 19816 | 110544438 |
| Atrial thrombosis | 19.00 | 13.62 | 12 | 25033 | 4334 | 110559920 |
| Hepatic enzyme increased | 18.98 | 13.62 | 27 | 25018 | 320865 | 110243389 |
| Pleural effusion | 18.84 | 13.62 | 85 | 24960 | 177624 | 110386630 |
| Thoracotomy | 18.69 | 13.62 | 5 | 25040 | 190 | 110564064 |
| Haemophilic arthropathy | 18.16 | 13.62 | 5 | 25040 | 212 | 110564042 |
| Parenteral nutrition | 17.96 | 13.62 | 7 | 25038 | 893 | 110563361 |
| Wound | 17.93 | 13.62 | 16 | 25029 | 234421 | 110329833 |
| Extravasation | 17.81 | 13.62 | 12 | 25033 | 4833 | 110559421 |
| Urine ketone body present | 17.77 | 13.62 | 11 | 25034 | 3835 | 110560419 |
| Liver injury | 17.66 | 13.62 | 6 | 25039 | 150407 | 110413847 |
| Therapeutic product effect incomplete | 17.45 | 13.62 | 15 | 25030 | 223790 | 110340464 |
| Nasopharyngitis | 17.23 | 13.62 | 40 | 25005 | 394321 | 110169933 |
| Osteoarthritis | 17.18 | 13.62 | 10 | 25035 | 182613 | 110381641 |
| Pain in extremity | 17.10 | 13.62 | 55 | 24990 | 487063 | 110077191 |
| Heparin resistance | 17.06 | 13.62 | 5 | 25040 | 266 | 110563988 |
| Fibroma | 17.03 | 13.62 | 7 | 25038 | 1025 | 110563229 |
| Mouth haemorrhage | 16.99 | 13.62 | 18 | 25027 | 13470 | 110550784 |
| Urticaria | 16.98 | 13.62 | 127 | 24918 | 318730 | 110245524 |
| Cholestasis | 16.97 | 13.62 | 42 | 25003 | 64476 | 110499778 |
| Venoocclusive liver disease | 16.90 | 13.62 | 19 | 25026 | 15188 | 110549066 |
| Gastrointestinal disorder | 16.78 | 13.62 | 18 | 25027 | 241934 | 110322320 |
| Disseminated intravascular coagulation | 16.73 | 13.62 | 32 | 25013 | 41254 | 110523000 |
| Intracardiac thrombus | 16.72 | 13.62 | 11 | 25034 | 4257 | 110559997 |
| Intentional product use issue | 16.59 | 13.62 | 19 | 25026 | 247887 | 110316367 |
| Arthralgia | 16.58 | 13.62 | 106 | 24939 | 779526 | 109784728 |
| Blood bilirubin increased | 16.46 | 13.62 | 46 | 24999 | 75926 | 110488328 |
| Anti factor VIII antibody positive | 16.38 | 13.62 | 4 | 25041 | 105 | 110564149 |
| Haemophilia | 16.34 | 13.62 | 4 | 25041 | 106 | 110564148 |
| Cancer pain | 16.32 | 13.62 | 13 | 25032 | 6759 | 110557495 |
| Weight decreased | 16.32 | 13.62 | 53 | 24992 | 468004 | 110096250 |
| Bronchial artery embolisation | 16.21 | 13.62 | 3 | 25042 | 19 | 110564235 |
| Hospitalisation | 16.19 | 13.62 | 6 | 25039 | 142487 | 110421767 |
| Haemorrhagic disorder | 16.17 | 13.62 | 8 | 25037 | 1805 | 110562449 |
| Sepsis | 16.10 | 13.62 | 128 | 24917 | 327218 | 110237036 |
| Hepatic cyst ruptured | 16.07 | 13.62 | 3 | 25042 | 20 | 110564234 |
| Infusion site discomfort | 16.07 | 13.62 | 8 | 25037 | 1829 | 110562425 |
| Traumatic haemorrhage | 16.04 | 13.62 | 8 | 25037 | 1836 | 110562418 |
| Spontaneous haemorrhage | 15.97 | 13.62 | 7 | 25038 | 1201 | 110563053 |
| Postpartum haemorrhage | 15.86 | 13.62 | 8 | 25037 | 1881 | 110562373 |
| Swelling | 15.83 | 13.62 | 35 | 25010 | 351006 | 110213248 |
| Urinary tract disorder | 15.78 | 13.62 | 12 | 25033 | 5832 | 110558422 |
| Pulmonary alveolar haemorrhage | 15.63 | 13.62 | 21 | 25024 | 20129 | 110544125 |
| Rectal haemorrhage | 15.57 | 13.62 | 61 | 24984 | 119772 | 110444482 |
| Fall | 15.56 | 13.62 | 77 | 24968 | 603405 | 109960849 |
| PCO2 abnormal | 15.47 | 13.62 | 4 | 25041 | 133 | 110564121 |
| Pulseless electrical activity | 15.40 | 13.62 | 19 | 25026 | 16738 | 110547516 |
| Premature delivery | 15.30 | 13.62 | 26 | 25019 | 30606 | 110533648 |
| HER2 positive breast cancer | 15.23 | 13.62 | 5 | 25040 | 388 | 110563866 |
| Allergic reaction to excipient | 15.19 | 13.62 | 6 | 25039 | 793 | 110563461 |
| Myelodysplastic syndrome | 15.13 | 13.62 | 29 | 25016 | 37455 | 110526799 |
| Sinus tachycardia | 15.06 | 13.62 | 32 | 25013 | 44461 | 110519793 |
| Platelet count abnormal | 15.01 | 13.62 | 12 | 25033 | 6270 | 110557984 |
| Ischaemia | 14.91 | 13.62 | 14 | 25031 | 9069 | 110555185 |
| Neuromuscular blocking therapy | 14.90 | 13.62 | 3 | 25042 | 31 | 110564223 |
| Adnexal torsion | 14.72 | 13.62 | 5 | 25040 | 431 | 110563823 |
| Uterine leiomyoma | 14.72 | 13.62 | 13 | 25032 | 7787 | 110556467 |
| Fibrin degradation products increased | 14.71 | 13.62 | 5 | 25040 | 432 | 110563822 |
| Arterial thrombosis | 14.61 | 13.62 | 9 | 25036 | 3110 | 110561144 |
| Cyanosis | 14.53 | 13.62 | 25 | 25020 | 29716 | 110534538 |
| Memory impairment | 14.40 | 13.62 | 14 | 25031 | 196930 | 110367324 |
| Haematoma | 14.27 | 13.62 | 37 | 25008 | 58439 | 110505815 |
| Obesity | 14.24 | 13.62 | 4 | 25041 | 113347 | 110450907 |
| Infusion site rash | 14.24 | 13.62 | 8 | 25037 | 2335 | 110561919 |
| Psoriasis | 14.14 | 13.62 | 7 | 25038 | 139986 | 110424268 |
| Device related infection | 14.05 | 13.62 | 29 | 25016 | 39490 | 110524764 |
| Intentional self-injury | 13.94 | 13.62 | 28 | 25017 | 37401 | 110526853 |
| Pneumonia | 13.91 | 13.62 | 277 | 24768 | 876437 | 109687817 |
| Neutrophil count decreased | 13.69 | 13.62 | 59 | 24986 | 120882 | 110443372 |
| Ventricular tachycardia | 13.63 | 13.62 | 33 | 25012 | 49976 | 110514278 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B02AA02 | BLOOD AND BLOOD FORMING ORGANS ANTIHEMORRHAGICS ANTIFIBRINOLYTICS Amino acids |
| MeSH PA | D000933 | Antifibrinolytic Agents |
| MeSH PA | D003029 | Coagulants |
| MeSH PA | D006401 | Hematologic Agents |
| MeSH PA | D006490 | Hemostatics |
| FDA PE | N0000175632 | Decreased Fibrinolysis |
| FDA EPC | N0000175634 | Antifibrinolytic Agent |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:48675 | antifibrinolytic drug |
| CHEBI has role | CHEBI:50248 | hematologic agent |
| CHEBI has role | CHEBI:55324 | gastrointestinal drug |
| CHEBI has role | CHEBI:62868 | hepatoprotective agent |
| CHEBI has role | CHEBI:63726 | neuroprotective agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:73336 | vulnerary |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
Related Drugs by ATC class:
B02AA Amino acids 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Contraception | indication | 13197004 | |
| Female hypogonadism syndrome | indication | 16041008 | |
| Endometriosis | indication | 129103003 | |
| Menorrhagia | indication | 386692008 | |
| Hemorrhaging in Hemophilia | indication | ||
| Refractory melasma | off-label use | 36209000 | |
| Epistaxis | off-label use | 249366005 | |
| Hyperfibrinolysis Induced Hemorrhage | off-label use | ||
| Prevention of Hemorrhage with Cardiovascular Instability from Cardiopulmonary Bypass - CABG | off-label use | ||
| Postsurgical Hemorrhage | off-label use | ||
| Heart valve disorder | contraindication | 368009 | DOID:4079 |
| Cerebral edema | contraindication | 2032001 | |
| Hypercholesterolemia | contraindication | 13644009 | |
| Subarachnoid intracranial hemorrhage | contraindication | 21454007 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Depressive disorder | contraindication | 35489007 | |
| Migraine | contraindication | 37796009 | DOID:6364 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
| Body fluid retention | contraindication | 43498006 | |
| Thrombosis of retinal vein | contraindication | 46085004 | |
| Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
| Benign mammary dysplasia | contraindication | 57993004 | |
| Obstructive hyperbilirubinemia | contraindication | 59848001 | |
| Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
| Intermenstrual bleeding - irregular | contraindication | 64996003 | |
| Cerebral arterial thrombosis | contraindication | 71444005 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Malignant neoplasm of liver | contraindication | 93870000 | DOID:3571 |
| Deep venous thrombosis | contraindication | 128053003 | |
| Angina pectoris | contraindication | 194828000 | |
| Impaired renal function disorder | contraindication | 197663003 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Pulmonary thromboembolism | contraindication | 233935004 | |
| Thrombophilia | contraindication | 234467004 | DOID:2452 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Cholestasis of pregnancy | contraindication | 235888006 | |
| Endometrial carcinoma | contraindication | 254878006 | DOID:2871 |
| Pregnancy, function | contraindication | 289908002 | |
| Hypertriglyceridemia | contraindication | 302870006 | |
| Malignant tumor of cervix | contraindication | 363354003 | DOID:4362 |
| Thromboembolic disorder | contraindication | 371039008 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Ligneous conjunctivitis | contraindication | 403435005 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Estrogen receptor positive tumor | contraindication | 416053008 | |
| Porphyria | contraindication | 418470004 | |
| Thrombosis | contraindication | 439127006 | |
| Hypertensive urgency | contraindication | 443482000 | |
| Carcinoma of female breast | contraindication | 447782002 | |
| Smokes tobacco daily | contraindication | 449868002 | |
| Major Surgery with Prolonged Post-Operative Immobilization | contraindication | ||
| Nonspecific Abnormal Papanicolaou Smear of Cervix | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.31 | acidic |
| pKa2 | 10.7 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Plasminogen | Enzyme | INHIBITOR | Kd | 5.96 | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020569 | VUID |
| N0000148271 | NUI |
| D01136 | KEGG_DRUG |
| 4020569 | VANDF |
| C0040613 | UMLSCUI |
| CHEBI:48669 | CHEBI |
| CHEMBL877 | ChEMBL_ID |
| DB00302 | DRUGBANK_ID |
| D014148 | MESH_DESCRIPTOR_UI |
| 5526 | PUBCHEM_CID |
| 2060 | INN_ID |
| 6573 | IUPHAR_LIGAND_ID |
| 6T84R30KC1 | UNII |
| 10691 | RXNORM |
| 5607 | MMSL |
| 80873 | MMSL |
| d00529 | MMSL |
| 002073 | NDDF |
| 109006003 | SNOMEDCT_US |
| 386960009 | SNOMEDCT_US |
| 6T84R30KC1 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cyklokapron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0013-1114 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | NDA | 30 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-0960 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 30 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3720 | TABLET, FILM COATED | 650 mg | ORAL | ANDA | 25 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14593-318 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | ANDA | 2 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-115 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 26 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-166 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | ANDA | 26 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-524 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | ANDA | 23 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-909 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 18 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-910 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 18 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-415 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 28 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-415 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 28 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-418 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 27 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-1000 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 31 sections |
| TRANEXAMIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-189 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 28 sections |
| TRANEXAMIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-314 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 28 sections |
| TRANEXAMIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43066-008 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 27 sections |
| TRANEXAMIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43066-008 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 27 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4530 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 30 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-772 | TABLET | 650 mg | ORAL | NDA authorized generic | 28 sections |
| TRANEXAMIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1532 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 16 sections |
| TRANEXAMIC ACID IN SODIUM CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-0108 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | NDA | 25 sections |
| Tranexamic Acid | Human Prescription Drug Label | 1 | 55150-188 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 28 sections |
| TRANEXAMIC ACID | Human Prescription Drug Label | 1 | 59651-839 | TABLET | 650 mg | ORAL | ANDA | 27 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6169 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 28 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-750 | TABLET | 650 mg | ORAL | ANDA | 29 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-265 | TABLET | 650 mg | ORAL | ANDA | 29 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8599 | TABLET, FILM COATED | 650 mg | ORAL | ANDA | 26 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8838 | TABLET, FILM COATED | 650 mg | ORAL | ANDA | 26 sections |
| Tranexamic Acid | Human Prescription Drug Label | 1 | 65145-106 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 27 sections |
| TRANEXAMIC ACID IN SODIUM CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-534 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 26 sections |